SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?

Kardiol Pol. 2024;82(1):3-4. doi: 10.33963/v.phj.98860. Epub 2024 Jan 17.

Authors

Davide Capodanno¹, Simone Finocchiaro²

Affiliations

¹ Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy. [email protected].
² Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.

PMID: 38230484
DOI: 10.33963/v.phj.98860

No abstract available

MeSH terms

Acute Kidney Injury* / chemically induced
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Percutaneous Coronary Intervention* / adverse effects
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents